The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / How to Differentiate Between & Manage Hypereosinophilic Syndromes & EGPA

How to Differentiate Between & Manage Hypereosinophilic Syndromes & EGPA

February 2, 2022 • By Samantha C. Shapiro, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2021—Hypereosinophilic syndromes (HES) include a wide array of rare diseases characterized by peripheral eosinophilia and end-organ involvement. Because eosinophilic granulomatosis with polyangiitis (EGPA) occupies the space between HES and vasculitis, rheumatologists are often tasked with diagnosing and managing other HES, as well. Amy D. Klion, MD, chief of the Human Eosinophil Section, U.S. National Institutes of Health and National Institutes for Allergy and Infectious Diseases (NIH/NIAID), Bethesda, Md., provided a detailed overview of the EGPA and HES spectrum at ACR Convergence 2021, Nov. 3–9, 2021.

You Might Also Like
  • Vasculitis Guidelines in Focus, Part 3: EGPA
  • Case Report: Could Myocarditis + Shortness of Breath = EGPA?
  • How to Manage Critical Illness in Patients with Autoimmune Disease
Also By This Author
  • Practical Ways to Manage Cardiovascular Risk in Patients with Psoriatic Arthritis

Hypereosinophilic Syndromes

HES is an umbrella category for several clinical subtypes. In the NIH cohort, greater than 50% fall into the idiopathic HES (iHES) category.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Despite extensive evaluation, no apparent etiology is identified, and the clinical picture does not fit one of the defined subtypes,” Dr. Klion said. “Further, a subset of patients [with an idiopathic hypereosinophilic syndrome] is completely asymptomatic and have no evidence of end-organ involvement.”1

Overlap HES is also common. Example: A single-organ eosinophilic disorder, such as chronic eosinophilic pneumonia, may overlap with iHES, or EGPA may overlap with HES. “This is important to recognize [because] the therapeutic approach may be different,” she said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Marked eosinophilia may also occur in a variety of myeloid neoplasms and myeloproliferative disorders. Platelet-derived growth factor receptor-α (PDGFRα) associated myeloid neoplasm is the most common in this category. It’s caused by an interstitial deletion in chromosome 4 that leads to a constitutively activated fusion tyrosine kinase. Fortunately, this variant is sensitive to imatinib. Before imatinib, three-year mortality was 30%.2

EGPA

Although most rheumatologists think of EGPA as separate from HES, the signs and symptoms are similar. Anti-neutrophil cytoplasmic antibodies (ANCA) are positive in less than 50% of patients with biopsy-proven EGPA, so we cannot rely on ANCA testing alone to differentiate the two. EGPA and HES with asthma or sinusitis show overlapping serum biomarker profiles, so we cannot rely on this profile to separate them either.3

“So are EGPA and HES a spectrum or an overlap?” Dr. Klion asked.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Recent studies have shown that ANCA-positive EGPA patients are more likely to have neurologic involvement, renal involvement and purpura, but less likely to have cardiac involvement. Relapses are more common in the ANCA-positive group, but mortality is increased in the ANCA-negative group.4,5

How should we approach ANCA-negative EGPA patients who don’t fall into a neat little box?  Dr. Klion said, “Most of the patients with EGPA/HES overlap are ANCA negative. So when we have an HES patient who has features of EGPA without biopsy-proven vasculitis, we treat them the way the 2021 ACR/Vasculitis Foundation Guideline for the Treatment and Management of ANCA-Associated Vasculitis would recommend you treat EGPA. But if they don’t respond to this approach, we try another agent that works for both, [such as] mepolizumab. Fortunately, mepolizumab is now FDA approved for the treatment of both HES and EGPA, so insurance approval has gotten easier.”6

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports, Vasculitis Tagged With: ACR Convergence 2021, EGPA, eosinophil, eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndromes (HES)

You Might Also Like:
  • Vasculitis Guidelines in Focus, Part 3: EGPA
  • Case Report: Could Myocarditis + Shortness of Breath = EGPA?
  • How to Manage Critical Illness in Patients with Autoimmune Disease
  • What Rheumatologists Should Know About Childhood-Onset SLE & Vasculitis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)